Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Endocrine Cancer Mobile
ENDOCRINE CANCER ADVISOR
Endocrine Cancer News
Aggressive Subtypes of Papillary Thyroid Cancer Deserve Increased Attention
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups.
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
How to Help Patients With Cancer Find Trustworthy Information Online
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
Gender Bias in Oncology: Q&A With Dr Narjust Duma
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Factors Associated With Thyroid Cancer Overtreatment Identified
Overtreatment more likely in younger, male, Hispanic or Asian patients, those with extensive lymph node surgery.
Radiation From CT Scans Linked to Thyroid Cancer, Leukemia
Elevated risk stronger in women than men; risk for non-Hodgkin lymphoma increased in patients ≤45.
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Practice Setting Linked to Receipt of More Costly Cancer Drugs
Receiving cancer treatment at a non–National Cancer Institute-designated Comprehensive Cancer Center was associated with higher drug cost, a cohort study found.
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
Want to read more?
Please login or register first to view this content.
